Vera Therapeutics, Inc.

NASDAQ:VERA

Biotechnology

Healthcare
$25.58 +0.27%

+$0.09 today

Market cap
$1.85B
Beta
0.95
P/E (TTM)
-6.8
EPS (TTM)
-$5.16
52W Low $19.07High $56.05

Volume 0.95M

Average 1.18M

VERA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Vera Therapeutics, Inc.NASDAQ: VERA

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue remains negative

Q2 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $0.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How VERA compares with its peers on the latest reported figures

  • VERA's LTM Jun 2026 cost of revenue of $0 is the 9th highest of the 10 companies compared; the peer median is $1.98M.
VERA Competitors Peer median
Cost of Revenue for VERA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PHARPharming Group N.V.LTM Mar 2026$46.97M +32.9%+37.5%12.7%
ARQTArcutis Biotherapeutics, Inc.LTM Jun 2026$41.1M +43.0%+265.1%8.9%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$2.34M +7090.5%——
BHVNBiohaven Ltd.LTM Jun 2026$2.07M ———
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.98M -86.0%-44.1%23.7%
ALMSAlumis Inc. Common StockLTM Jun 2026$871K +6.2%+140.9%11.8%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$866K -97.1%——
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$76K ——4.0%
VERAVera Therapeutics, Inc.LTM Jun 2026$0 ———
ANABAnaptysBio, Inc.LTM Mar 2026-$38.15M -122.7%-69.9%16.4%
Peer median (excluding VERA) $1.98M+6.2%+37.5%12.2%

Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0(846K)000
Gross Profit0846K000
Gross Margin—————
Research & Development22.48M69.84M78.23M126.17M215.26M
Selling, General & Admin11.92M21.91M23.79M41M100.22M
Operating Expenses34.4M91.75M102.01M167.17M315.47M
Depreciation & Amortization176K(846K)21K105K468K
EBITDA(32.41M)(88.91M)(92.18M)(144.42M)(291.62M)
EBITDA Margin—————
Operating Income(34.4M)(90.9M)(102.01M)(167.17M)(315.47M)
Operating Margin—————
Interest Income15K1.75M7.98M20.71M24.48M
Interest Expense20K992K3.79M7.63M7.53M
Other Income / Expenses1.79M1.85M6.02M15.02M15.86M
Income Before Tax(32.61M)(89.06M)(95.99M)(152.15M)(299.61M)
Pre-Tax Margin—————
Income Tax Expense1K1K1K1K1K
Net Income(32.61M)(89.06M)(95.99M)(152.15M)(299.62M)
Net Margin—————
EPS (Basic)(2.43)(3.35)(2.25)(2.75)(4.66)
EPS (Diluted)(2.43)(3.35)(2.25)(2.75)(4.66)
Weighted Avg Shares13.44M26.57M42.71M55.33M64.23M
Weighted Avg Shares (Diluted)13.44M26.57M42.71M55.33M64.23M

Vera Therapeutics, Inc.

NASDAQ:VERA

Intrinsic Alpha fair value

Locked

Current Price

$25.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.